Clinical Trial

EX02 CAR-T Cells for Relapsed and Refractory Acute Myeloid Leukemia

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated October 15, 2024 (before its estimated August 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a early Phase 1 open-label, single-arm clinical study of EX02 CAR-T therapy for relapsed and refractory acute myeloid leukemia. Each participant will undergo leukapheresis after enrolment, receive treatment of the conditioning chemotherapy of cyclophosphamide and fludarabine, and an an intravenous infusion of CAR-T cells. Each participant will proceed through the following study procedures: * Screening * Enrollment/Leukapheresis * Conditioning chemotherapy * CAR T treatment * Post-treatment assessment * Long-term follow-up
Trial Details
NCT Number NCT06642025
Lead Sponsor Zhimin Zhai
Collaborators: Zeno Therapeutics Pte. Ltd
Conditions Acute Myeloid Leukemia (AML), CAR-T
Enrollment 9 participants
Start Date 2024-09-01
Primary Completion 2026-08-01 (estimated)
Study Completion 2029-09-01 (estimated)
Updated on ClinicalTrials.gov 2024-10-15